Recruiting

Brain Imaging

Sponsor:

National Institute on Aging (NIA)

Code:

NCT00966017

Conditions

Down Syndrome

Alzheimer's Disease

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD). The study hypothesis is that PET imaging of small molecule probes, in the form of novel fluorescent dyes with radioactive labels, will demonstrate cerebral patterns in patients with AD that are distinct from those of age-matched persons who are cognitively intact.

Conditions

Down Syndrome

Alzheimer's Disease

Study ID

NCT00966017

Start date

Jul, 2009

Status verified date

Dec, 2009

Completion date

Feb, 2014

Anticipated

Primary completion date

Feb, 2014

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 45 years or older
  • No significant cerebrovascular disease - modified Ischemic Score of < 4
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Screening laboratory tests and ECG without significant abnormalities that might interfere with the study

Additional Inclusion Criteria for Controls

  • MMSE score between 24 and 30 (unless < 8 years of educational achievement)
  • The following medications are allowed if stable for > 1 month: antidepressants (without anticholinergic effects) if not currently depressed and no history of major depression for 2 years; estrogen replacement therapy; thyroid replacement therapy as long as individual is euthyroid; antihypertensives that do not influence cognitive function

Additional Inclusion Criteria for Individuals with Down syndrome

  • Family member or caregiver available; caregiver relationship 2 years or longer
  • Karyotype DX of trisomy or translocation DS Mosaic form of Down syndrome
  • English-speaking

Exclusion Criteria:

  • Evidence of neurological or other physical illness that could produce cognitive deterioration; volunteers with a history of TIAs, carotid bruits, or lacunes on MRI scan will be excluded
  • Parkinson's Disease
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer
  • Major psychiatric disorders, such as bipolar disorder or schizophrenia
  • Medicines that could influence psychometric test results
  • Use of any of the following drugs: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin
  • Current diagnosis or history of alcoholism or drug dependence
  • Evidence of untreated depression or untreated anxiety
  • Use of any investigational drugs within the previous month or longer, depending on drug half-life
  • Contraindication for MRI scan (e.g., metal in body, claustrophobia)
  • Diagnosis of possible or probable AD or any other dementia (e.g., vascular, Lewy body, frontotemporal) or MCI

Additional Exclusion Criteria for Individuals with Down syndrome

  • Mosaic form of Down syndrome
  • History of clinically significant neurological disorder or disease and Psychiatric diagnosis or treatment within 3 months prior to screening

Study Design

Enrollment

108 participants

Anticipated

Interventions and Outcome Measures

Arms

DS

Those with Down syndrome

Non-DS

Healthy controls

Central Contacts and Locations

Central contacts

Locations

UCLA

Recruiting

Los Angeles, California, United States, 90024

Contacts

Principal Investigator:

Gary W. Small, MD

More Information

Sponsor

National Institute on Aging (NIA)

Last update posted

Dec 29, 2009

Last verified

Dec, 2009

Keywords

  • PET Scan

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by National Institute on Aging (NIA) on 2009-12-29.